89 related articles for article (PubMed ID: 36723981)
1. Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma.
Shaya JA; McKay RR
Ann Transl Med; 2019 Dec; 7(Suppl 8):S385. PubMed ID: 32016103
[No Abstract] [Full Text] [Related]
2. Update on combined immunotherapy for the treatment of advanced renal cell carcinoma.
Gebrael G; Sahu KK; Agarwal N; Maughan BL
Hum Vaccin Immunother; 2023 Dec; 19(1):2193528. PubMed ID: 37062953
[TBL] [Abstract][Full Text] [Related]
3. The emerging landscape of neo/adjuvant immunotherapy in renal cell carcinoma.
Dibajnia P; Cardenas LM; Lalani AA
Hum Vaccin Immunother; 2023 Dec; 19(1):2178217. PubMed ID: 36775257
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
[TBL] [Abstract][Full Text] [Related]
5. Endoscopic ultrasound-guided placement of fiducial markers for stereotactic body radiation therapy of pancreatic metastases from renal cell carcinoma.
Polkowski M; Pawlewicz K; Skoczylas K; Wrońska E; Lenarcik M; Reguła J
Endoscopy; 2023 Dec; 55(S 01):E876-E877. PubMed ID: 37442168
[No Abstract] [Full Text] [Related]
6. Spatially-aware clustering improves AJCC-8 risk stratification performance in oropharyngeal carcinomas.
Canahuate G; Wentzel A; Mohamed ASR; van Dijk LV; Vock DM; Elgohari B; Elhalawani H; Fuller CD; Marai GE
Oral Oncol; 2023 Sep; 144():106460. PubMed ID: 37390759
[TBL] [Abstract][Full Text] [Related]
7. Deep radiomic model based on the sphere-shell partition for predicting treatment response to chemotherapy in lung cancer.
Chang R; Qi S; Wu Y; Yue Y; Zhang X; Guan Y; Qian W
Transl Oncol; 2023 Sep; 35():101719. PubMed ID: 37320871
[TBL] [Abstract][Full Text] [Related]
8. Homogenization of multi-institutional chest x-ray images in various data transformation schemes.
Kim H; Lee S; Shim WJ; Choi MS; Cho S
J Med Imaging (Bellingham); 2023 Nov; 10(6):061103. PubMed ID: 37125408
[TBL] [Abstract][Full Text] [Related]
9. Radiomics model and clinical scale for the preoperative diagnosis of silent corticotroph adenomas.
Wang H; Chang J; Zhang W; Fang Y; Li S; Fan Y; Jiang S; Yao Y; Deng K; Lu L; Bao X; Feng F; Wang R; Feng M
J Endocrinol Invest; 2023 Sep; 46(9):1843-1854. PubMed ID: 37020103
[TBL] [Abstract][Full Text] [Related]
10. Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic.
Lyskjær I; Iisager L; Axelsen CT; Nielsen TK; Dyrskjøt L; Fristrup N
Clin Cancer Res; 2024 Feb; 30(4):663-672. PubMed ID: 37874628
[TBL] [Abstract][Full Text] [Related]
11. [Immunotherapy of Renal Cell Carcinoma].
Poprach A; Lakomý R; Büchler T
Klin Onkol; 2017; 30(Supplementum3):55-61. PubMed ID: 29239194
[TBL] [Abstract][Full Text] [Related]
12. Radiomics for Renal Cell Carcinoma: Predicting Outcomes from Immunotherapy and Targeted Therapies-A Narrative Review.
Rallis KS; Kleeman SO; Grant M; Ordidge KL; Sahdev A; Powles T
Eur Urol Focus; 2021 Jul; 7(4):717-721. PubMed ID: 33994170
[TBL] [Abstract][Full Text] [Related]
13. Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Iribe Y; Furuya M; Shibata Y; Yasui M; Funahashi M; Ota J; Iwashita H; Nagashima Y; Hasumi H; Hayashi N; Makiyama K; Kondo K; Tanaka R; Yao M; Nakaigawa N
Fam Cancer; 2021 Jan; 20(1):75-80. PubMed ID: 32666341
[TBL] [Abstract][Full Text] [Related]
14. Radiomics to predict immunotherapy efficacy in advanced renal cell carcinoma: A retrospective study.
Rossi E; Boldrini L; Maratta MG; Gatta R; Votta C; Tortora G; Schinzari G
Hum Vaccin Immunother; 2023 Dec; 19(1):2172926. PubMed ID: 36723981
[TBL] [Abstract][Full Text] [Related]
15. Update on immunotherapy for renal cancer.
Canales Rojas R
Medwave; 2021 Jun; 21(5):e8202. PubMed ID: 34214067
[TBL] [Abstract][Full Text] [Related]
16. Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma.
Chen L; Douglass J; Kleinberg L; Ye X; Marciscano AE; Forde PM; Brahmer J; Lipson E; Sharfman W; Hammers H; Naidoo J; Bettegowda C; Lim M; Redmond KJ
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(4):916-925. PubMed ID: 29485071
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
